Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 334 participants.
Also called NCT03312855
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 334 participants
- Sponsor
- Registry
-
NCT03312855
-
- Other papers using this trial's data
- Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT03312855. Randomized; quadruple masking; primary purpose treatment. Start 2017-11-20 (actual); primary completion 2020-02-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept
- Acronym
- ISAR-PLASTER
- Condition
- Stable Coronary Artery Disease
- Intervention (Drug)
- Revacept 80 mg
- Intervention (Drug)
- Revacept 160 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Deutsches Herzzentrum Muenchen
- Collaborator
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Collaborator
- AdvanceCor GmbH
- Collaborator
- Technical University of Munich
- Collaborator
- German Federal Ministry of Education and Research
Record details
- Record id
cardio:ct-nct03312855- Content hash
6fb2394c3b9a0e6eed8f7d53a7db7327d60a890ec7b663907c082c9a2c192ea9